Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 954
-SubTopic 310
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481027/954-310-50-2

+ Details

Name:	us-gaap_ConcentrationRiskLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Summary of Significant Accounting Policies - Significant Concentrations (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 04, 2023	Feb. 26, 2022	Feb. 27, 2021
Revenue from Contract with Customer, Segment Benchmark [Member] \| Customers \| Top five third party payors \| Pharmacy sales
Significant Concentrations
Percentage of concentration risk	83.40%
Revenue from Contract with Customer, Segment Benchmark [Member] \| Customers \| Largest third party payor \| Caremark \| Pharmacy sales
Significant Concentrations
Percentage of concentration risk	33.40%	32.10%	30.40%
Revenue from Contract with Customer, Segment Benchmark [Member] \| Customers \| Medicaid agencies and related managed care Medicaid payors \| Pharmacy sales
Significant Concentrations
Percentage of concentration risk	19.90%
Revenue from Contract with Customer, Segment Benchmark [Member] \| Customers \| Largest Medicaid agency \| Pharmacy sales
Significant Concentrations
Percentage of concentration risk	6.60%
Revenue from Contract with Customer, Segment Benchmark [Member] \| Customers \| Medicare PartD \| Pharmacy sales
Significant Concentrations
Percentage of concentration risk	38.80%
Purchases \| Suppliers \| McKesson Corp. \| Pharmacy sales
Significant Concentrations
Percentage of concentration risk	98.00%
Pharmacy Services Segment \| Medicare PartD
Significant Concentrations
Net revenues	$ 529,025	$ 589,620	$ 630,104
Pharmacy Services Segment \| Revenue from Contract with Customer, Segment Benchmark [Member] \| Customers \| Top Five Customers [Member]
Significant Concentrations
Percentage of concentration risk	65.90%
Pharmacy Services Segment \| Revenue from Contract with Customer, Segment Benchmark [Member] \| Customers \| Previously Disclosed Client Loss [Member]
Significant Concentrations
Percentage of concentration risk	6.90%
Pharmacy Services Segment \| Revenue from Contract with Customer, Segment Benchmark [Member] \| Customers \| Largest Payor [Member]
Significant Concentrations
Percentage of concentration risk	43.10%	41.10%	36.60%
Pharmacy Services Segment \| Consolidated revenues \| Customers \| Medicare PartD
Significant Concentrations
Percentage of concentration risk	2.20%	2.40%	2.60%